Propella Therapeutics, Inc., a private, clinical-stage biopharmaceutical company developing best-in-class oncology therapeutics, announced the dosing of the first patient in the Phase 1/2a clinical trial studying its lead patented product candidate, PRL-02 (abiraterone decanoate), for the treatment of metastatic prostate cancer.
Propella Therapeutics, Inc., a biopharmaceutical company focused on developing innovative, best-in-class oncology drugs, announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for PRL-02 (abiraterone decanoate), a potentially best-in-class therapy for metastatic prostate cancer. Propella also announced the appointment of Brendan Griffin to its leadership team as Chief Financial Officer.
Propella Therapeutics, Inc. (Propella Therapeutics), a leader in the development of innovative, best-in-class prescription products, and the National Cancer Institute (NCI), announced they have entered into a Cooperative Research and Development Agreement (CRADA). Under this new partnership, Propella Therapeutics and NCI will conduct a multi-center clinical trial to evaluate abiraterone decanoate, as a new therapy for metastatic prostate cancer.
Propella Therapeutics Inc., a leader in the development of innovative best-in-class prescription products, today announced the issuance of a U.S. patent for a new drug treatment for metastatic prostate cancer. The patent covers new molecules that are designed to provide significant advantages over the current standard of care.
Vizuri Health Sciences LLC has completed a strategic reorganization to form two new corporations. The new entities are Propella Therapeutics Inc., focusing on prescription drugs, and Vizuri Health Sciences Consumer Healthcare Inc., developing non-prescription pain management products.
The American College of Rheumatology (ACR), an organization of physicians and health professionals that advances education, research, advocacy and practice support for the care of people with arthritis, has announced updated 2019 treatment guidelines for the management of OA of the hand, hip, and knee.
Vizuri Health Sciences LLC to Present CGS-200-5 Knee Pain Results at the American College of Rheumatology Annual Meeting
Vizuri Health Sciences LLC Granted New US Patent for Novel Topical Analgesic Formulations Containing Capsaicin
Press Release: Vizuri Health Sciences LLC Initiates a U.S. Phase 2 Osteoarthritis (OA) Knee Pain Study with Prescription-Strength Topical Capsaicin Formulation, CGS-200 June 11, 2018 07:58 AM Eastern Daylight Time FAIRFAX, Va.–(EON: Enhanced Online News)–Vizuri Health Sciences LLC, a pharmaceutical and over-the-counter (OTC) product development company, today announced the initiation of clinical study VZU00025: A Phase […]